Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) Net Income towards Common Stockholders: 2019-2024

Historic Net Income towards Common Stockholders for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to -$376.7 million.

  • Beam Therapeutics' Net Income towards Common Stockholders fell 16.61% to -$112.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$414.6 million, marking a year-over-year decrease of 188.77%. This contributed to the annual value of -$376.7 million for FY2024, which is 184.28% down from last year.
  • As of FY2024, Beam Therapeutics' Net Income towards Common Stockholders stood at -$376.7 million, which was down 184.28% from -$132.5 million recorded in FY2023.
  • Beam Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$132.5 million during FY2023, with a 5-year trough of -$376.7 million in FY2024.
  • For the 3-year period, Beam Therapeutics' Net Income towards Common Stockholders averaged around -$266.1 million, with its median value being -$289.1 million (2022).
  • In the last 5 years, Beam Therapeutics' Net Income towards Common Stockholders skyrocketed by 54.16% in 2023 and then tumbled by 184.28% in 2024.
  • Beam Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$195.9 million in 2020, then plummeted by 89.23% to -$370.6 million in 2021, then rose by 22.00% to -$289.1 million in 2022, then soared by 54.16% to -$132.5 million in 2023, then plummeted by 184.28% to -$376.7 million in 2024.